Close vote by FDA advisers favors propoxyphene withdrawal.
Traynor
Kate
K
D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D011431:Dextropropoxyphene / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D010146:Pain / Q000188:drug therapy; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
D000701:Analgesics, Opioid; D011431:Dextropropoxyphene